Comparative Pharmacology
Head-to-head clinical analysis: ENSKYCE versus NORLESTRIN FE 1 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENSKYCE versus NORLESTRIN FE 1 50.
ENSKYCE vs NORLESTRIN FE 1/50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ENSKYCE (fospropofol disodium) is a prodrug of propofol. It is hydrolyzed by alkaline phosphatases to release propofol, which acts as a positive allosteric modulator of GABA-A receptors, enhancing chloride conductance and producing sedation and anesthesia.
Combination of ethinyl estradiol and norethindrone acetate provides negative feedback on gonadotropin release, suppressing ovulation. Also causes cervical mucus thickening and endometrial thinning.
2 g IV every 8 hours over 5 hours on days 1-3 of each 21-day cycle
One tablet (norethindrone 1 mg and ethinyl estradiol 50 mcg plus ferrous fumarate 75 mg) orally once daily for 28 days, with 21 active tablets and 7 placebo tablets.
None Documented
None Documented
12 hours (terminal); allows once-daily dosing in most patients
Norethindrone: 5-12 hours (mean 8 hours). Ethinyl estradiol: 11-16 hours. Clinical context: Steady state reached in 5-7 days.
Renal: ~70% unchanged; Biliary/Fecal: ~20% as metabolites
Norethindrone: 20% renal, 80% fecal. Ethinyl estradiol: 40% renal, 60% fecal.
Category C
Category C
Oral Contraceptive
Oral Contraceptive